CTOs on the Move

Corvus Pharmaceuticals

www.corvuspharma.com

 
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. With accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.
  • Number of Employees: 5K-10K
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Corvus Pharmaceuticals raised $75M on 09/28/2015
Corvus Pharmaceuticals raised $31.8M on 02/12/2021

Similar Companies

MBL

MBL is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AdPharma

AdPharma is a Arlington Heights, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bioforward

Bioforward is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cue Health

Cue Health is a health technology company that develops and manufactures portable, compact, connected medical diagnostic products that help people, organizations, and communities protect human health. Headquartered in San Diego, California, our mission is to empower healthcare providers and organizations by increasing their access to rapid, accurate, actionable health data in real-time. We have built a culture that is dynamic, innovative, and results-oriented. We seek driven and talented individuals to join our multi-disciplinary engineering, regulatory, clinical, operations, production, and testing teams. If you`re ready to help us reinvent the future of healthcare, reach out to us today.

Elucida Oncology

Elucida Oncology, Inc., is a clinical development stage company based on proprietary ultra-small C-Dot technology to find, see and treat an array of solid tumor cancers. Developed and clinically translated by Memorial Sloan-Kettering Cancer Center and Cornell University, C-Dots have published human safety and tumor-specific clinical data. Elucida Oncology is currently progressing through a broad clinical trial program while continuing to drive a future portfolio through ongoing innovation.